Recall Effectiveness Checks: FDA Tips
This article was originally published in The Gray Sheet
Executive Summary
Conducting device recall effectiveness checks can be tricky. Two FDA officials offer advice to make the process work smoother and explain why unique device identification will be helpful.
You may also be interested in...
FDA Issues UDI Final Rule, Removes Direct Marking Requirement For Implants
The long-awaited unique device identifier final rule is intended to help FDA, device companies and health care providers track medical devices. The rule addresses many of industry’s concerns with FDA’s initial proposal and was met with general support by companies.
CDRH Terminating High-Risk Device Recalls Faster As Class I’s Increase In 2012
As the number of class I recalls climbed to a historic high in 2012, CDRH was already taking action to more quickly terminate such high-risk recalls. The device center beefed up its class I recall close-out process by developing a template to standardize terminations and ensure that recalls were appropriately addressed by manufacturers. “What we’re looking to do is to move beyond just removing the recalled device from the shelf,” CDRH official Ann Ferriter said. Officials at device firms Philips Medical Systems and Cordis sense that FDA has become more stringent, requiring nearly 100 percent of product pulled from the market before declaring a recall closed. Meanwhile, CDRH is tackling recall-related provisions outlined in the FDA Safety and Innovation Act, and an ex-FDA official explains why he believes the number of overall recalls jumped 9 percent in 2012.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.